Loading...
Loading...
VERA| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | -0.5M |
| Gross Profit | 0.5M |
| Operating Expense | 31.3M |
| Operating I/L | -31.3M |
| Other Income/Expense | 1.2M |
| Interest Income | 1.6M |
| Pretax | -30.1M |
| Income Tax Expense | -0.3M |
| Net Income/Loss | -29.8M |
Vera Therapeutics, Inc. is a clinical stage biotechnology company in the United States, specializing in developing and commercializing treatments for serious immunological diseases. The company's lead product candidate, atacicept, is a fusion protein administered via subcutaneous injection and is currently in Phase IIb clinical trial for patients with immunoglobulin A nephropathy. Additionally, Vera Therapeutics is developing MAU868, a monoclonal antibody for the treatment of BK viremia infections, which is in Phase 2 clinical trial. These innovative therapies form the core of the company's revenue generation strategy.
